Xortx announces us atm offering

Calgary, alberta, nov. 30, 2023 (globe newswire) -- xortx therapeutics inc. ("xortx" or the “company”) (nasdaq: xrtx | tsxv: xrtx | frankfurt: anu), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that it has entered into an at the market offering agreement with h.c. wainwright & co., llc (“wainwright”), pursuant to which the company, at its discretion, may offer and sell, from time to time, through wainwright, common shares without par value (the “shares”) having an aggregate offering price of up to us$3,701,931 (the “atm offering”). a cash commission of 3.0% on the aggregate gross proceeds raised under the atm offering will be paid to wainwright in connection with its services.
XRTX Ratings Summary
XRTX Quant Ranking